| Primary |
| Herpes Zoster |
65.7% |
| Herpes Simplex |
7.5% |
| Oral Herpes |
3.8% |
| Pyrexia |
3.8% |
| Pain |
2.7% |
| Asthma |
1.9% |
| Genital Herpes |
1.9% |
| Chronic Hepatitis |
1.6% |
| Vomiting |
1.6% |
| Myelodysplastic Syndrome |
1.3% |
| Nausea |
1.3% |
| Herpes Zoster Ophthalmic |
1.1% |
| Antiviral Prophylaxis |
0.8% |
| Diabetes Mellitus |
0.8% |
| Essential Hypertension |
0.8% |
| Gastric Mucosal Lesion |
0.8% |
| Headache |
0.8% |
| Herpes Virus Infection |
0.8% |
| Bipolar Disorder |
0.5% |
| Chemotherapy |
0.5% |
|
| Vomiting |
10.9% |
| Rhabdomyolysis |
8.7% |
| Loss Of Consciousness |
6.5% |
| White Blood Cell Count Decreased |
6.5% |
| Convulsion |
5.8% |
| Nausea |
5.1% |
| Pyrexia |
5.1% |
| Rash |
5.1% |
| Somnolence |
5.1% |
| Blood Pressure Decreased |
4.3% |
| Decreased Appetite |
4.3% |
| Syncope |
4.3% |
| White Blood Cell Count Increased |
4.3% |
| Hallucination |
3.6% |
| Malaise |
3.6% |
| Palpitations |
3.6% |
| Renal Failure Acute |
3.6% |
| Urticaria |
3.6% |
| Muscular Weakness |
2.9% |
| Tremor |
2.9% |
|
| Secondary |
| Herpes Zoster |
18.6% |
| Pyrexia |
14.2% |
| Product Used For Unknown Indication |
12.5% |
| Myelodysplastic Syndrome |
8.4% |
| Nausea |
7.1% |
| Vomiting |
7.1% |
| Hepatitis Chronic Active |
4.1% |
| Herpes Simplex |
4.1% |
| Drug Exposure During Pregnancy |
3.4% |
| Antiviral Prophylaxis |
3.0% |
| Bipolar Disorder |
3.0% |
| Drug Use For Unknown Indication |
3.0% |
| Multiple Sclerosis |
2.4% |
| Pain |
2.4% |
| Sleep Disorder |
1.7% |
| Depression |
1.4% |
| Analgesic Therapy |
1.0% |
| Genital Herpes |
1.0% |
| Herpes Virus Infection |
1.0% |
| Fatigue |
0.7% |
|
| Stress |
15.2% |
| Syncope |
7.6% |
| Blood Alkaline Phosphatase Increased |
6.1% |
| Hallucination |
6.1% |
| Myalgia |
6.1% |
| Pancreatic Carcinoma |
6.1% |
| Urine Output Decreased |
6.1% |
| Hepatocellular Injury |
4.5% |
| Rhabdomyolysis |
4.5% |
| Sedation |
4.5% |
| Tinnitus |
4.5% |
| Urticaria |
4.5% |
| Blood Pressure Decreased |
3.0% |
| Decreased Appetite |
3.0% |
| Drug Ineffective |
3.0% |
| Heart Rate Increased |
3.0% |
| Herpes Zoster |
3.0% |
| Pelvic Kidney |
3.0% |
| Pneumonia |
3.0% |
| Pyrexia |
3.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
14.7% |
| Drug Use For Unknown Indication |
11.5% |
| Acne |
8.6% |
| Prophylaxis |
8.2% |
| Hiv Infection |
7.9% |
| Multiple Myeloma |
7.6% |
| Pain |
6.4% |
| Chronic Lymphocytic Leukaemia |
3.7% |
| Depression |
3.6% |
| Infection Prophylaxis |
3.0% |
| Nausea |
3.0% |
| Ovarian Cancer |
3.0% |
| Hypertension |
2.9% |
| Premedication |
2.8% |
| Herpes Zoster |
2.5% |
| Insomnia |
2.4% |
| Diabetes Mellitus |
2.4% |
| Gastrooesophageal Reflux Disease |
2.0% |
| Osteoporosis Prophylaxis |
2.0% |
| Anxiety |
2.0% |
|
| Sepsis |
8.9% |
| Vomiting |
8.3% |
| Rash |
6.7% |
| Vision Blurred |
6.1% |
| Wheezing |
6.1% |
| White Blood Cell Count Decreased |
5.6% |
| Wound |
5.6% |
| Thrombocytopenia |
5.0% |
| Weight Decreased |
5.0% |
| Drug Ineffective |
4.4% |
| Pneumonia |
4.4% |
| Weight Increased |
4.4% |
| Septic Shock |
3.9% |
| Syncope |
3.9% |
| Urge Incontinence |
3.9% |
| Urinary Incontinence |
3.9% |
| White Blood Cell Count Increased |
3.9% |
| Abdominal Pain |
3.3% |
| Platelet Count Decreased |
3.3% |
| Renal Failure Acute |
3.3% |
|
